Search research articles
Contact Us
Filters
Showing results (31-40 of 85) with videos related to
Page
of 9
Sort By:
Clinical Lymphoma, Myeloma & Leukemia
|
November 8, 2024
Longitudinal Assessment of Transfusion Intensity in Patients With JAK Inhibitor-Naive or -Experienced Myelofibrosis Treated With Momelotinib
Claire N Harrison, Ruben Mesa, Moshe Talpaz, et al.
Leukemia & Lymphoma
|
July 14, 2020
Feasibility of thiotepa addition to the fludarabine-busulfan conditioning with tacrolimus/sirolimus as graft vs host disease prophylaxis
María Laura Fox, Irene García-Cadenas, Ariadna Martínez Pérez, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation
|
January 7, 2018
CD34<sup>+</sup> Cell Selection versus Reduced-Intensity Conditioning and Unmodified Grafts for Allogeneic Hematopoietic Cell Transplantation in Patients Age >50 Years with Acute Myelogenous Leukemia and Myelodysplastic Syndrome
Pere Barba, Rodrigo Martino, Qin Zhou, et al.
European Journal of Haematology
|
December 24, 2016
Predictive factors for anemia response to erythropoiesis-stimulating agents in myelofibrosis
Juan-Carlos Hernández-Boluda, Juan-Gonzalo Correa, Regina García-Delgado, et al.
European Journal of Haematology
|
October 7, 2020
Ex vivo T-cell depletion vs post-transplant cyclophosphamide, sirolimus, and mycophenolate mofetil as graft-vs-host disease prophylaxis for allogeneic hematopoietic stem cell transplantation
Juan Montoro, Elisa Roldán, José Luis Piñana, et al.
Bone Marrow Transplantation
|
June 24, 2024
Post-transplant cyclophosphamide compared to sirolimus/tacrolimus in reduced intensity conditioning transplants for patients with lymphoid malignancies
Maria Laura Fox, Irene García-Cadenas, Victor Navarro, et al.
Cancers
|
May 14, 2022
Impact of Individual Comorbidities on Survival of Patients with Myelofibrosis
María García-Fortes, Juan C Hernández-Boluda, Alberto Álvarez-Larrán, et al.
Future Oncology (London, England)
|
January 11, 2021
MOMENTUM: momelotinib vs danazol in patients with myelofibrosis previously treated with JAKi who are symptomatic and anemic
Srdan Verstovsek, Chih-Cheng Chen, Miklós Egyed, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research
|
February 4, 2024
Meaningful Symptomatic Change in Patients With Myelofibrosis From the SIMPLIFY Studies
Stacie Hudgens, Srdan Verstovsek, Lysbeth Floden, et al.
Hemasphere
|
October 30, 2023
Patient-reported Outcomes and Quality of Life in Anemic and Symptomatic Patients With Myelofibrosis: Results From the MOMENTUM Study
Ruben A Mesa, Claire Harrison, Jeanne M Palmer, et al.
Page
of 9
Search research articles
Search
Showing results (31-40 of 85) with videos related to
Sort By:
Page
of 9
Clinical Lymphoma, Myeloma & Leukemia
|
November 8, 2024
Longitudinal Assessment of Transfusion Intensity in Patients With JAK Inhibitor-Naive or -Experienced Myelofibrosis Treated With Momelotinib
Claire N Harrison, Ruben Mesa, Moshe Talpaz, et al.
Leukemia & Lymphoma
|
July 14, 2020
Feasibility of thiotepa addition to the fludarabine-busulfan conditioning with tacrolimus/sirolimus as graft vs host disease prophylaxis
María Laura Fox, Irene García-Cadenas, Ariadna Martínez Pérez, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation
|
January 7, 2018
CD34<sup>+</sup> Cell Selection versus Reduced-Intensity Conditioning and Unmodified Grafts for Allogeneic Hematopoietic Cell Transplantation in Patients Age >50 Years with Acute Myelogenous Leukemia and Myelodysplastic Syndrome
Pere Barba, Rodrigo Martino, Qin Zhou, et al.
European Journal of Haematology
|
December 24, 2016
Predictive factors for anemia response to erythropoiesis-stimulating agents in myelofibrosis
Juan-Carlos Hernández-Boluda, Juan-Gonzalo Correa, Regina García-Delgado, et al.
European Journal of Haematology
|
October 7, 2020
Ex vivo T-cell depletion vs post-transplant cyclophosphamide, sirolimus, and mycophenolate mofetil as graft-vs-host disease prophylaxis for allogeneic hematopoietic stem cell transplantation
Juan Montoro, Elisa Roldán, José Luis Piñana, et al.
Bone Marrow Transplantation
|
June 24, 2024
Post-transplant cyclophosphamide compared to sirolimus/tacrolimus in reduced intensity conditioning transplants for patients with lymphoid malignancies
Maria Laura Fox, Irene García-Cadenas, Victor Navarro, et al.
Cancers
|
May 14, 2022
Impact of Individual Comorbidities on Survival of Patients with Myelofibrosis
María García-Fortes, Juan C Hernández-Boluda, Alberto Álvarez-Larrán, et al.
Future Oncology (London, England)
|
January 11, 2021
MOMENTUM: momelotinib vs danazol in patients with myelofibrosis previously treated with JAKi who are symptomatic and anemic
Srdan Verstovsek, Chih-Cheng Chen, Miklós Egyed, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research
|
February 4, 2024
Meaningful Symptomatic Change in Patients With Myelofibrosis From the SIMPLIFY Studies
Stacie Hudgens, Srdan Verstovsek, Lysbeth Floden, et al.
Hemasphere
|
October 30, 2023
Patient-reported Outcomes and Quality of Life in Anemic and Symptomatic Patients With Myelofibrosis: Results From the MOMENTUM Study
Ruben A Mesa, Claire Harrison, Jeanne M Palmer, et al.
Page
of 9